Case Reports

SCC supports the practice of evidence-based cannabinoid medicine. This collection of research studies exists to guide clinical decision making. All included articles have been vetted by Board members to ensure that only rigorous, unbiased, and non-commercialized studies are included.


Entry ID19

Medical ConditionAdverse effects


Retinitis Pigmentosa progression may be slowed by cannabis
Medical Condition
Adverse effects
Vision loss, headaches, depression
A 37 y/o PhD university research associate with retinitis pigmentosa found relief of associated symptoms with cannabis and subjective slowdown in progression of vision loss.
Patient information
Brief history and target symptomatology
This 37 y/o PhD university research associate was diagnosed with retinitis pigmentosa (RP) at age 14. He experiences progressive vision loss, headaches, depression and insomnia.
Previous and current conventional therapies
Supplementation with antioxidant vitamins was ineffective. Serial electroretinopathies (ERG) were discontinued in the belief that the flashes of light used further damage his retina and "ophthalmologists only want photographs for their own collection". His eyeglass prescription is reviewed annually to compensate for his increasing tunnel vision. He has not found significant improvement in his mood with psychotherapy.
Clinical response to Cannabis
Stress, mood, headaches and insomnia have all improved with cannabis use.
Additional Comments
RP is a genetic disease found in 1 in 4000 people in the US. In patient's case, it was traced to mutations in both parents' X chromosome. There is no known cure; valproic acid, gene therapy and retinal transplantation are currently in the research stage. Administration of a THC analog to rats with chemically induced RP has shown reduction in the rate of degeneration of retinal photoreceptors. .
Reference: Experimental Eye Research (2014), 120:175-185
Usual method of Cannabis administration
Frequency of Usage: Time Per Day
Frequency of Usage: Days per Week